Bachem Holding AG

Bachem Holding AG

Health CarePharmaceuticals and Biotechnology
  • Price (CHF)88.30
  • Today's Change2.40 / 2.79%
  • Shares traded69.09k
  • 1 Year change-10.54%
  • Beta1.0810
Data delayed at least 15 minutes, as of Mar 27 2023 16:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bachem Holding AG is a Switzerland-based biochemical company that provides services to the pharmaceutical and biotechnology industry. The Company focuses on the process development and manufacturing of peptides and organic molecules as active pharmaceutical ingredients (APIs), as well as on the development of biochemical products for research purposes. Its product portfolio comprises fluorescent dyes for the fluorescence energy transfer (FRET) analysis of receptor-ligand interactions, protein-protein interactions and the cleavage of substrate molecules, as well as glycosylated peptides for the manipulation of drug properties. The Company markets products under the Bachem and Clinalfa brands and operates production facilities in Switzerland and in the United States.

  • Revenue in CHF (TTM)531.74m
  • Net income in CHF100.68m
  • Incorporated1971
  • Employees1.78k
  • Location
    Bachem Holding AGHauptstrasse 144BUBENDORF 4416SwitzerlandCHE
  • Phone+41 619352333
  • Fax+41 619352324
  • Websitehttp://www.bachem.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Dechra Pharmaceuticals plc817.96m45.13m3.28bn2.04k71.033.4522.234.010.3590.3596.527.390.49751.676.87356,974.502.743.553.064.0057.1556.745.527.221.4011.540.377996.3512.1413.674.8617.3948.5015.93
Krka d.d. Novo Mesto1.70bn359.71m3.41bn11.49k8.981.547.242.0011.6911.6955.2568.380.65751.473.94--13.9212.2616.8414.6756.7357.5021.1718.042.42--0.0055--9.696.2817.4918.94-3.27--
Dottikon ES Holding AG283.87m74.30m3.53bn670.0046.934.6137.4412.455.385.3820.5554.730.31660.46415.14426,878.208.296.739.677.5675.5981.9126.1719.641.78--0.0383--15.0910.6713.3321.7523.13--
Richter Gedeon Vegyeszeti Gyar Nyrt2.07bn400.50m3.58bn12.18k8.941.326.761.73835.11835.114,308.655,646.290.64592.404.34--12.6510.1914.5311.6457.3656.2119.5916.562.35--0.0142--27.3012.5611.4377.2812.38--
Hikma Pharmaceuticals Plc2.32bn173.00m4.16bn8.84k24.742.1111.871.800.67570.67579.157.930.56931.703.36232,942.904.329.135.6812.5450.2650.867.5915.511.146.700.373931.08-1.415.39-55.34--8.301.43
Grifols SA-99.01bn-99.01bn5.28bn23.25k--0.9631----------9.04----------3.21--4.03--41.82--9.750.7425--0.5355--22.927.0310.36-20.663.06--
DiaSorin SpA-99.01bn-99.01bn5.65bn3.35k--------------------------16.63--19.02--67.86--24.99------25.2440.4316.8025.4622.5825.685.59
Orion Oyj1.33bn346.05m5.82bn3.53k16.766.4214.864.382.482.489.536.481.021.697.54380,096.4026.7120.4032.7825.5763.3260.4326.0821.152.04--0.190792.5028.785.3480.349.79-0.90511.99
BACHEM HOLDING AG531.74m100.68m6.44bn1.78k63.025.4148.0812.121.361.367.2115.870.39651.243.83299,403.707.519.318.4511.2232.2131.6118.9319.392.758.770.000658.795.6615.24-12.2119.2424.806.40
Swedish Orphan Biovitrum AB (publ)1.66bn232.86m6.68bn1.56k27.652.7314.984.038.848.8463.0089.610.37151.414.33--5.217.466.809.4674.5876.3814.0319.580.53039.150.25550.0021.0023.61-1.5318.0960.32--
Recordati Industria Chimica e Farma SpA1.83bn309.25m8.04bn4.30k25.875.1618.534.381.501.508.907.520.54391.745.53--9.1712.8211.8616.3869.4271.0516.8522.480.811415.900.526161.8417.297.55-19.081.5845.876.23
Ipsen SA3.13bn587.34m8.64bn5.74k15.452.579.342.766.747.3234.7540.450.59562.105.27--11.209.9114.7813.8083.2882.0018.8115.231.5847.090.190421.115.249.43-8.2617.050.98543.71
Data as of Mar 27 2023. Currency figures normalised to Bachem Holding AG's reporting currency: Swiss Franc CHF

Institutional shareholders

14.31%Per cent of shares held by top holders
HolderShares% Held
Capital Research & Management Co. (World Investors)as of 10 Mar 20233.70m5.02%
Premier Fund Managers Ltd.as of 30 Nov 2022945.97k1.28%
BlackRock Investment Management (UK) Ltd.as of 28 Feb 2023923.97k1.25%
VV Verm�gensverwaltung AGas of 30 Nov 2022870.88k1.18%
The Vanguard Group, Inc.as of 03 Mar 2023817.37k1.11%
Capital Research & Management Co. (Global Investors)as of 31 Dec 2022773.48k1.05%
UBS Asset Management Switzerland AGas of 28 Feb 2023691.02k0.94%
Vontobel Asset Management AGas of 28 Feb 2023678.10k0.92%
Credit Suisse Asset Management (Schweiz) AGas of 28 Feb 2023583.80k0.79%
abrdn Investment Management Ltd.as of 28 Feb 2022560.79k0.76%
More ▼
Data from 30 Nov 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.